Clinical Outcomes and Therapeutic Strategies of Hodgkin Lymphoma
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 4682
Special Issue Editor
Special Issue Information
Dear Colleagues,
In 1961, the National Institute of Health researchers devised a regimen consisting of mechlorethamine, vincristine, procarbazine, and prednisone (the MOPP regimen), which was able to cure about half of patients with Hodgkin lymphoma (HL). This was the first chemotherapy regimen to cure patients and a revolution in oncology, offering hope to millions of patients suffering from malignant neoplasms. However, we have made significant improvements in curing HL with novel regimens such as BEACOPPesc and ABVD. After years of research, we have seen also an overall survival benefit with the immunochemotherapy regimen brentuximab vedotin+AVD in advanced stages. HL is certainly a story of success, yet few patients represent unmet needs being refractory to or relapsing after first-line therapy. The incorporation of brentuximab vedotin in salvage regimens has improved the outcomes of these patients. As a last resort, allogeneic stem cell transplantation remains a valid strategy.
This Special Issue aims to share different experiences with HL, regardless of the line of treatment, pointing out the similarities and diversities of our approach to HL.
Both original articles and the state-of-art reviews are welcome.
As a Guest Editor, I hope that this Special Issue will follow the success of our treatment of HL.
Dr. Vibor Milunović
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hodgkin lymphoma
- ABVD protocol
- BEACOPP protocol
- hematopoietic stem cell transplantation
- brentuximab vedotin
- immune checkpoint inhibitors
- long term survivor
- quality of life
- pediatrics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
